Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NTX-348
- Development stage
- Preclinical
- Lead developer
- Nimbus Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NTX-348 is an orally active, small molecule inhibitor of solute carrier family 15 member 4 (SLC15A4) developed by Nimbus Therapeutics. SLC15A4 is a lysosomal peptide transporter that plays a critical role in endolysosomal Toll-like receptor (TLR7, TLR8, and TLR9) signaling by interacting with the adapter protein TASL to recruit and activate the transcription factor IRF5. By inhibiting SLC15A4, NTX-348 promotes the intracellular degradation of TASL and blocks the production of inflammatory cytokines and type I interferons. It is being investigated as a potential therapeutic approach for systemic lupus erythematosus (SLE) and other immune-mediated diseases.
02
Targets
SLC15A4 (Solute carrier family 15 member 4)
Beyond the preview
Go deeper on NTX-348.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NTX-348.